ArticleGynecologic oncology reports2026
Folate receptor alpha expression in uterine serous carcinoma: a single-institution analysis.
Article in Gynecologic oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uterine serous carcinoma (USC) is an aggressive histologic subtype of endometrial cancer for which limited targeted therapeutic options exist. Folate receptor alpha (FOLRα) is an established therapeutic target in high-grade serous ovarian carcinoma, but its expression patterns in USC remain poorly characterized. We sought to evaluate the prevalence and distribution of FOLRα expression in USC and assess the applicability of ovarian cancer-derived FOLRα thresholds to this histology. We conducted a retrospective review of patients with pathologically confirmed USC treated at a single institution from 2017 to 2024. FOLRα expression was assessed using the VENTANA FOLR1 (FOLR1-2.1) RxDx assay. Positivity was defined as ≥75% of tumor cells demonstrating moderate-to-strong membranous staining (PS2+ scoring). Seventy-three patients were included. Median age was 71 years; 53% had uterine-confined disease at presentation. In our cohort, nine tumors (12.3%) met the high-expression threshold for FOLRα positivity. An additional 13 tumors (17.8%) demonstrated intermediate expression, while 69.9% showed <50% staining. FOLRα expression in USC is variable, and only a minority of tumors met the high-expression threshold used for mirvetuximab soravtansine (MIRV) eligibility in ovarian cancer. However, nearly one-third demonstrated medium-to-high expression, suggesting that FOLRα targeting may not be fully captured by ovarian cancer-derived biomarker cutoffs in this disease process. These descriptive, hypothesis-generating findings support further evaluation of FOLRα-directed strategies, including combination approaches, in prospective studies of USC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.